Etoperidone

From WikiMD's WELLNESSPEDIA

An antidepressant drug

Etoperidone

Etoperidone
Chemical structure of Etoperidone






























Etoperidone is a pharmaceutical drug that was developed as an antidepressant. It belongs to the class of drugs known as serotonin antagonist and reuptake inhibitors (SARIs). Although it was never marketed in the United States, it has been used in some European countries.

Pharmacology[edit]

Etoperidone functions primarily as a serotonin antagonist and reuptake inhibitor, which means it blocks the reuptake of serotonin in the brain, increasing its availability in the synaptic cleft. This action is believed to contribute to its antidepressant effects. Additionally, etoperidone has been shown to have affinity for various neurotransmitter receptors, including alpha-adrenergic, dopaminergic, and histaminergic receptors.

Clinical Use[edit]

Etoperidone was primarily used in the treatment of major depressive disorder. Its efficacy in alleviating symptoms of depression was comparable to other antidepressants available at the time. However, due to the development of newer antidepressants with improved safety profiles and fewer side effects, etoperidone is not commonly used today.

Side Effects[edit]

The side effects of etoperidone are similar to those of other antidepressants in its class. Common side effects include drowsiness, dry mouth, and dizziness. Some patients may experience gastrointestinal disturbances such as nausea and vomiting. As with other antidepressants, there is a risk of serotonin syndrome if taken in combination with other serotonergic drugs.

Mechanism of Action[edit]

Etoperidone's mechanism of action involves the inhibition of serotonin reuptake, which increases serotonin levels in the brain. This is thought to improve mood and alleviate depressive symptoms. Additionally, its antagonistic effects on various neurotransmitter receptors may contribute to its overall therapeutic profile.

Development and History[edit]

Etoperidone was developed in the 1970s by the pharmaceutical company Angelini. It was part of a wave of new antidepressants that sought to improve upon the side effect profiles of earlier drugs. Despite its initial promise, etoperidone was overshadowed by the development of selective serotonin reuptake inhibitors (SSRIs) and other newer classes of antidepressants.

Related pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.